{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:56:24Z","timestamp":1790927784341,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gen Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11748-026-02319-2","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T06:56:25Z","timestamp":1779519385000},"page":"1013-1021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical predictors of pathological response after immunotherapy in salvage surgery for non-small cell lung cancer: a supplementary analysis of the CReGYT-05 immune checkpoint inhibitor-salvage study"],"prefix":"10.1007","volume":"74","author":[{"given":"Satoshi","family":"Takamori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Tane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Nishikubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinkichi","family":"Takamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"2319_CR1","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2017;377:1919\u201329.","journal-title":"N Engl J Med"},{"key":"2319_CR2","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342\u201350.","journal-title":"N Engl J Med"},{"key":"2319_CR3","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med"},{"key":"2319_CR4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"2319_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/jso.26691","volume":"125","author":"A Smith","year":"2022","unstructured":"Smith A, Wali A, Montes A, Hadaki M, Harrison-Phipps K, Karapanagiotou EM, et al. Salvage pulmonary resection in stage IIIB\u2013IV lung cancer after treatment with immune checkpoint inhibitors case series and literature review. J Surg Oncol. 2022;125:290\u20138.","journal-title":"J Surg Oncol"},{"key":"2319_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/jso.27920","volume":"131","author":"M Schiavon","year":"2025","unstructured":"Schiavon M, Cannone G, Bertolaccini L, Gallina FT, Pezzuto F, Lorenzoni G, et al. Safety and efficacy of salvage surgery after treatment with immune-checkpoint adjuvant inhibitors for advanced non-small cell lung cancer: a multicentric study. J Surg Oncol. 2025;131:371\u20139.","journal-title":"J Surg Oncol"},{"key":"2319_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70209","volume":"16","author":"K Seto","year":"2025","unstructured":"Seto K, Horio Y, Masago K, Sasaki E, Kuroda H, Matsubayashi Y, et al. Salvage surgery following systemic therapy in initially unresectable non-small-cell lung cancer. Thorac Cancer. 2025;16:e70209.","journal-title":"Thorac Cancer"},{"key":"2319_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezaf156","volume":"67","author":"R Werner","year":"2025","unstructured":"Werner R, Eisenberg MA, Hooda Z, Ries S, Papasotiropoulos T, Steinmann N, et al. Perioperative and long-term survival outcomes following resection of stage IV non-small-cell lung cancer: a multi-centre experience. Eur J Cardiothorac Surg. 2025;67:ezaf156.","journal-title":"Eur J Cardiothorac Surg"},{"key":"2319_CR9","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.21037\/jtd-24-891","volume":"16","author":"M Hamaji","year":"2024","unstructured":"Hamaji M, Ozasa H, Sakamori Y, Terada K, Yoshizawa A, Kikuchi R, et al. Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer. J Thorac Dis. 2024;16:6094\u2013100.","journal-title":"J Thorac Dis"},{"key":"2319_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.xjon.2024.03.018","volume":"20","author":"A Nemeth","year":"2024","unstructured":"Nemeth A, Canavan ME, Zhan PL, Udelsman BV, Ely S, Wigle DA, et al. Salvage lung resection after immunotherapy is feasible and safe. JTCVS Open. 2024;20:141\u201350.","journal-title":"JTCVS Open"},{"key":"2319_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107294","volume":"182","author":"C Dickhoff","year":"2023","unstructured":"Dickhoff C, Unal S, Heineman DJ, Winkelman JA, Braun J, Bahce I, et al. Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation Durvalumab for unresectable stage III non-small cell lung cancer. Lung Cancer. 2023;182:107294.","journal-title":"Lung Cancer"},{"key":"2319_CR12","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s11748-022-01798-3","volume":"70","author":"T Ueno","year":"2022","unstructured":"Ueno T, Yamashita M, Yamashita N, Uomoto M, Kawamata O, Sano Y, et al. Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer. Gen Thorac Cardiovasc Surg. 2022;70:812\u20137.","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2319_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17182967","volume":"17","author":"MG Mastromarino","year":"2025","unstructured":"Mastromarino MG, Guerrini E, Caciagli LM, La Rosa A, Bacchin D, Aprile V, et al. Salvage surgery: a concrete opportunity in unresectable non-small cell lung cancer following definitive chemo-immunotherapy. Cancers (Basel). 2025;17:2967.","journal-title":"Cancers (Basel)"},{"key":"2319_CR14","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541\u20133.","journal-title":"J Clin Oncol"},{"key":"2319_CR15","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","volume":"19","author":"M Nishino","year":"2013","unstructured":"Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19:3936\u201343.","journal-title":"Clin Cancer Res"},{"key":"2319_CR16","doi-asserted-by":"crossref","unstructured":"Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510\u20137.","DOI":"10.1200\/JCO.2015.64.0391"},{"key":"2319_CR17","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973\u201385.","journal-title":"N Engl J Med"},{"key":"2319_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, Mart\u00ednez-Mart\u00ed A, Bernab\u00e9 R, Bosch-Barrera J, et al. Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2023;389:504\u201313.","journal-title":"N Engl J Med"},{"key":"2319_CR19","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29:1853\u201360.","journal-title":"Ann Oncol"},{"key":"2319_CR20","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1111\/1759-7714.14562","volume":"13","author":"ZY Chen","year":"2022","unstructured":"Chen ZY, Fu R, Tan XY, Yan LX, Tang WF, Qiu ZB, et al. Dynamic 18 F-FDG PET\/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Cancer. 2022;13:2524\u201331.","journal-title":"Thorac Cancer"},{"key":"2319_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2023.02.001","volume":"178","author":"F Zhuang","year":"2023","unstructured":"Zhuang F, Haoran E, Huang J, Wu J, Xu L, Zhang L, et al. Utility of 18F-FDG PET\/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. Lung Cancer. 2023;178:20\u20137.","journal-title":"Lung Cancer"},{"key":"2319_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-024-00772-x","volume":"24","author":"R Guo","year":"2024","unstructured":"Guo R, Yan W, Wang F, Su H, Meng X, Xie Q, et al. The utility of 18F-FDG PET\/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer. Cancer Imaging. 2024;24:120.","journal-title":"Cancer Imaging"},{"key":"2319_CR23","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-020-04711-3","volume":"47","author":"X Tao","year":"2020","unstructured":"Tao X, Li N, Wu N, He J, Ying J, Gao S, et al. The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2319_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours:\u3000revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2319_CR25","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2016","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th Edition. Union for International Cancer Control; 2016.","edition":"8th Edition"},{"issue":"Suppl 1","key":"2319_CR26","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150.","journal-title":"J Nucl Med"},{"key":"2319_CR27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280:576\u201384.","journal-title":"Radiology"},{"key":"2319_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12967-019-1828-0","volume":"17","author":"MG Dal Bello","year":"2019","unstructured":"Dal Bello MG, Filiberti RA, Alama A, Orengo AM, Mussap M, Coco S, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J Transl Med. 2019;17:74.","journal-title":"J Transl Med"},{"key":"2319_CR29","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/bjc.2017.45","volume":"116","author":"S Holdenrieder","year":"2017","unstructured":"Holdenrieder S, Wehnl B, Hettwer K, Simon K, Uhlig S, Dayyani F. Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis. Br J Cancer. 2017;116:1037\u201345.","journal-title":"Br J Cancer"}],"container-title":["General Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-026-02319-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11748-026-02319-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-026-02319-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:35:43Z","timestamp":1790926543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11748-026-02319-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2319"],"URL":"https:\/\/doi.org\/10.1007\/s11748-026-02319-2","relation":{},"ISSN":["1863-6705","1863-6713"],"issn-type":[{"value":"1863-6705","type":"print"},{"value":"1863-6713","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Akira Hamada has received lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Ethicon Japan K.K., Medtronic Japan Co., Ltd., and MSD K.K.; research funding from Chugai Pharmaceutical Co., Ltd. and AstraZeneca K.K. outside the submitted work. The other authors declare no conflicts of interest related to this study. No authors have any conflicts of interest related to this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}